Integra LifeSciences (NASDAQ:IART) Upgraded to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Integra LifeSciences (NASDAQ:IART) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

A number of other equities research analysts have also commented on IART. Wells Fargo & Company upped their price objective on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Friday, March 27th. Citigroup upped their price objective on shares of Integra LifeSciences from $9.00 to $11.00 and gave the company a “sell” rating in a research note on Wednesday. Argus reaffirmed a “hold” rating on shares of Integra LifeSciences in a research note on Wednesday, April 15th. Finally, Truist Financial reduced their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. Three investment analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $12.75.

Integra LifeSciences Trading Up 2.7%

IART opened at $13.92 on Friday. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $16.49. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.46. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -2.15 and a beta of 1.08. The company’s 50 day moving average price is $10.20 and its two-hundred day moving average price is $11.71.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The firm had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. During the same period in the previous year, the firm posted $0.41 EPS. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, research analysts predict that Integra LifeSciences will post 2.44 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Global Retirement Partners LLC acquired a new position in shares of Integra LifeSciences during the 4th quarter valued at $25,000. Osaic Holdings Inc. lifted its position in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after acquiring an additional 1,104 shares during the period. GAMMA Investing LLC lifted its position in shares of Integra LifeSciences by 145.9% during the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after acquiring an additional 3,742 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after acquiring an additional 6,814 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Integra LifeSciences during the 4th quarter valued at $124,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.